What is the normal anti‑Müllerian hormone (AMH) level for a 40‑year‑old woman?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Normal AMH for a 40-Year-Old Woman

For a 40-year-old woman, normal AMH levels typically range from approximately 0.5 to 3.0 ng/mL (or roughly 3.5 to 21 pmol/L), though values decline progressively with age and show considerable individual variation.

Age-Specific Reference Ranges

The evidence consistently demonstrates that AMH levels decline exponentially with advancing age. Multiple large population-based studies provide specific reference ranges for women around age 40:

  • Chinese population study (n=1,590): Women aged 37-40 years showed median AMH of 2.78 ng/mL with a reference range (5th-95th percentile) of 0.56-9.49 ng/mL 1

  • Another Chinese cohort (n=1,423): Women aged 36-40 years had median AMH of 1.07 µg/L (approximately 1.07 ng/mL) 2

  • Omani population study (n=319): Women aged 36-40 years showed median AMH of 13.71 pmol/L (approximately 1.92 ng/mL) with reference range of 2.15-48.91 pmol/L (0.30-6.86 ng/mL) 3

  • Korean infertility clinic data (n=16,972): Women aged 38-40 years had median AMH of 0.96 ng/mL 4

Key Clinical Considerations

AMH interpretation must account for multiple factors:

  • Assay variability: Different AMH assays (Gen II ELISA, Beckman Coulter, Elecsys Roche) produce different absolute values, making universal cut-offs problematic 5, 6

  • Population differences: Ethnic and geographic variations exist in AMH reference ranges, as demonstrated by differences between Chinese, Omani, and Korean populations 3, 1

  • Clinical context matters: AMH below 0.7-1.0 ng/mL is consistently associated with diminished ovarian reserve and increased miscarriage risk in women ≥35 years (OR 1.91-2.11) 7

Practical Interpretation Framework

For a 40-year-old woman:

  • AMH <0.5 ng/mL: Indicates significantly diminished ovarian reserve; associated with reduced fertility and higher miscarriage risk 7

  • AMH 0.5-3.0 ng/mL: Generally within expected range for age, though lower end suggests declining reserve

  • AMH >3.0 ng/mL: Above typical median for age 40; may suggest better ovarian reserve or possible polycystic ovarian morphology if accompanied by other features

Important Caveats

AMH should not be used in isolation. The 2023 international PCOS guidelines emphasize that AMH alone is insufficient for diagnosis and must be interpreted alongside clinical features, menstrual history, and ultrasound findings when indicated 5, 6.

Wide normal ranges exist. The 95th percentile values can be 10-15 times higher than 5th percentile values at any given age, reflecting substantial biological variability 3, 1. A single AMH value provides information about ovarian reserve but cannot predict individual fertility outcomes with certainty 8.

Menstrual cycle timing: While AMH is relatively stable across the menstrual cycle in older women, some fluctuation can occur, particularly in younger women 9.

References

Guideline

anti-müllerian hormone in pcos: a review informing international guidelines.

Trends in Endocrinology and Metabolism, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.